deltatrials
Completed PHASE2 INTERVENTIONAL 2-arm NCT06445075

Efficacy and Safety of Apitegromab for the Treatment of Adults Who Are Overweight or Obese (EMBRAZE)

A Phase 2 Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Apitegromab in Overweight and Obese Adult Subjects

Sponsor: Scholar Rock, Inc.

Updated 6 times since 2024 Last updated: Jan 20, 2026 Started: May 21, 2024 Primary completion: Mar 4, 2025 Completion: Jun 17, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Overweight and Obesity, this trial is completed. The trial is conducted by Scholar Rock, Inc. and has accumulated 6 data snapshots since 2024. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jul 2024 – ~Aug 2024 · 31 days · monthly snapshot~Aug 2024 – ~Sep 2024 · 31 days · monthly snapshot~Sep 2024 – ~Nov 2024 · 2 months · monthly snapshotRecruiting~Nov 2024 – ~Aug 2025 · 9 months · monthly snapshotActive Not Recruiting~Aug 2025 – ~Feb 2026 · 6 months · monthly snapshotCompleted~Feb 2026 – present · 5 months · monthly snapshotCompleted

Change History

6 versions recorded
  1. Feb 2026 — Present [monthly]

    Completed PHASE2

  2. Aug 2025 — Feb 2026 [monthly]

    Completed PHASE2

    Status: Active Not RecruitingCompleted

  3. Nov 2024 — Aug 2025 [monthly]

    Active Not Recruiting PHASE2

    Status: RecruitingActive Not Recruiting

  4. Sep 2024 — Nov 2024 [monthly]

    Recruiting PHASE2

  5. Aug 2024 — Sep 2024 [monthly]

    Recruiting PHASE2

Show 1 earlier version
  1. Jul 2024 — Aug 2024 [monthly]

    Recruiting PHASE2

    First recorded

May 2024

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Scholar Rock, Inc.
Data source: Scholar Rock, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .